By the numbers: Public Health England said in a statement Saturday that a research conducted by health officials from April 5 to May 16 found that:
- Two weeks after the second dose, the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the B.1.617 variant first detected in India, compared to 93% effectiveness against the B.1.1.7 variant first found in England.
- Two doses of the AstraZeneca vaccine were 60% effective against symptomatic disease from the B.1.617 variant compared to 66% effectiveness against the B.1.1.7 variant.
- Both vaccines were 33% effective against symptomatic disease from B.1.617, three weeks after the first dose compared to roughly 50% effectiveness against the B.1.1.7 variant.
What they're saying: Public Health England said in the statement that "we expect to see even higher levels of effectiveness against hospitalization and death" in regards to these vaccines.
- U.K. Health Secretary Matt Hancock said in the statement that due to this "groundbreaking" research gave officials confidence that those vaccinated against the coronavirus "have significant protection against this new variant."
Of note: The World Health Organization declared the B.1.617 coronavirus mutation a "variant of concern.
- German authorities have announced they will ban most non-essential travel from the U.K. from Sunday to prevent the spread of new coronavirus variants.
Go deeper: The race to avoid a possible "monster" COVID variant
